Retatrutide (also referred to as LY3437943) is an advanced triple receptor agonist peptide that simultaneously targets glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCGR) receptors. This triagonist mechanism distinguishes it from dual agonists such as tirzepatide, offering researchers a broader tool for exploring the interplay between incretin signalling pathways and energy balance regulation.
In preclinical and early clinical research, retatrutide has demonstrated significant interest in areas relating to metabolic dysfunction, adiposity modelling, glycaemic control, and appetite regulation. Its multi-receptor engagement allows investigation into synergistic hormonal pathways that govern fuel utilisation, hepatic lipid metabolism, and thermogenic activity.
Each vial contains 35mg of retatrutide supplied as a lyophilised powder with a purity of >98% as verified by HPLC analysis. The molecular formula is C₂₂₄H₃₅₀N₅₆O₆₅S, with a molecular weight of approximately 4963.5 g/mol. The CAS number is 2381272-73-5.
For optimal stability, store lyophilised product at -20°C, protected from light and moisture. Once reconstituted, keep refrigerated at 4°C and use within an appropriate timeframe per your research protocol.
Molecular Formula
C₂₂₄H₃₅₀N₅₈O₆₈S
Molecular Weight
4963.5 g/mol
Purity
>98%
CAS Number
2381272-73-5
Form
Lyophilised Powder
Research Applications
Metabolic disorder research, Obesity and adiposity modelling, Glycaemic regulation studies, Energy homeostasis investigation, Hepatic lipid metabolism research, Incretin signalling pathway analysis
For research purposes only. Not for human use.
Reviews
There are no reviews yet.